Abstract
Comments of Clinical and Microbiological Experience with Daptomycin in Chronic Osteomyelitis Treatment
Highlights
The use of daptomycin for the treatment of Chronic Osteomyelitis (CO) due to Staphylococcus aureus shows successful outcomes in the most complicated patients, and emerges as an option to be consider for elderly patients with several associated comorbidities
Arrest of DNA & RNA synthesis, toxin production, and protein synthesis follows, resulting in bacterial death without lysis of the cell wall, which gives a further advantage in diseases where inflammatory response associated counter antimicrobial use producing cell lysis [3,4,5], in addition, the in vitro potency of daptomycin has been demonstrated against Vancomycin resistant S. aureus (VRSA) and methicillin-resistant coagulase-negative staphylococci (MRCNS)
The most frequent side effect with daptomycin use is myopathy, but this mild myopathy was predicted and monitored by measuring serum creatine phosphokinase (CPK) concentration, and in the majority of cases, it was reversible upon the cessation of therapy [9]
Summary
The use of daptomycin (alone or in combination) for the treatment of Chronic Osteomyelitis (CO) due to Staphylococcus aureus shows successful outcomes in the most complicated patients, and emerges as an option to be consider for elderly patients with several associated comorbidities.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
